UPDATE: October, 2015
Retrophin Inc. is now testing Sparsentan in a clinical trial called the DUET study. There are over 50 study sites throughout the United States and Europe that are recruiting FSGS patients ages 8 to 75. To find a site near you, click here.
The purpose of the DUET study is to evaluate the safety and effectiveness of an investigational
medication in patients with focal segmental glomerulosclerosis (FSGS). The goal is to learn whether the investigational medication may change the amount of protein in the urine and decrease proteinuria. Click here to learn more about the DUET study, or call 877-659-5518.
Participation in research studies, like the DUET study, is essential for new and better treatments to become available for patients. For more information about participating in research studies, click here.
Original Article: January, 2015
Sparsentan Receives Orphan Drug Status
It was announced on January 9, 2015 that Sparsentan, a potential drug therapy for FSGS currently in clinical trials, was granted orphan-drug status by the US Food & Drug Administration (FDA). The FDA’s Orphan Drug Designation program was created to encourage companies to develop therapeutics for rare diseases, like FSGS. In the case of Sparsentan, if the drug is approved by FDA for FSGS, it will be marketed for seven years exclusively to treat the disease.
Sparsentan was licensed to Retrophin, Inc. by Ligand pharmaceuticals. When asked about the approval,President and Chief Executive Officer of Ligand Pharmaceuticals John Higgins said, “Sparsentan has the potential to be a significant medicine, and could transform the treatment of FSGS.”
For the drug to be approved, it must first pass clinical trials. Retrophin, Inc. is currently conducting a clinical trial called DUET to test the effectiveness of Sparsentan. Follow this link to learn more about DUET, and click here for a map detailing how and where to enroll to take part in this potentially groundbreaking study.
As always, we’ll keep you posted on updates to the DUET trial and other opportunities for FSGS and NS patients to learn more and participate in research designed to create better treatment options and cures for these conditions. Congratulations to Retrophin, Inc. and everyone involved in the DUET Clinical Study.
Learn more about Retrophin, Inc. here.